JP7498199B2 - 種々の疾患を処置するために有用なｂｃｋｄｋ阻害剤としての５－（チオフェン－２－イル）－１ｈ－テトラゾール誘導体 - Google Patents

種々の疾患を処置するために有用なｂｃｋｄｋ阻害剤としての５－（チオフェン－２－イル）－１ｈ－テトラゾール誘導体 Download PDF

Info

Publication number
JP7498199B2
JP7498199B2 JP2021576779A JP2021576779A JP7498199B2 JP 7498199 B2 JP7498199 B2 JP 7498199B2 JP 2021576779 A JP2021576779 A JP 2021576779A JP 2021576779 A JP2021576779 A JP 2021576779A JP 7498199 B2 JP7498199 B2 JP 7498199B2
Authority
JP
Japan
Prior art keywords
compound
pharma
acceptable salt
ceutically acceptable
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021576779A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538576A (ja
JP2022538576A5 (enExample
Inventor
クマール バタチャリア サミット
ライアン バトラー クリストファー
ジェイムズ フィリプスキ ケヴィン
リン カーモス べサニー
エンジェル マルティネス―アルシナ ルイ
アラン ミラー ラッセル
清之 大本
レイマー ブライアン
リチャード リース マシュー
ジェーン ロス フラック レイチェル
ザング ユアン
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2022538576A publication Critical patent/JP2022538576A/ja
Publication of JP2022538576A5 publication Critical patent/JP2022538576A5/ja
Application granted granted Critical
Publication of JP7498199B2 publication Critical patent/JP7498199B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021576779A 2019-06-28 2020-06-24 種々の疾患を処置するために有用なｂｃｋｄｋ阻害剤としての５－（チオフェン－２－イル）－１ｈ－テトラゾール誘導体 Active JP7498199B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962868542P 2019-06-28 2019-06-28
US62/868,542 2019-06-28
US202062960824P 2020-01-14 2020-01-14
US62/960,824 2020-01-14
PCT/IB2020/055974 WO2020261144A1 (en) 2019-06-28 2020-06-24 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases

Publications (3)

Publication Number Publication Date
JP2022538576A JP2022538576A (ja) 2022-09-05
JP2022538576A5 JP2022538576A5 (enExample) 2023-06-02
JP7498199B2 true JP7498199B2 (ja) 2024-06-11

Family

ID=71738227

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021576779A Active JP7498199B2 (ja) 2019-06-28 2020-06-24 種々の疾患を処置するために有用なｂｃｋｄｋ阻害剤としての５－（チオフェン－２－イル）－１ｈ－テトラゾール誘導体

Country Status (5)

Country Link
US (1) US20220363673A1 (enExample)
EP (1) EP3990452A1 (enExample)
JP (1) JP7498199B2 (enExample)
CA (1) CA3144848C (enExample)
WO (1) WO2020261144A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312296A (en) * 2021-12-01 2024-06-01 Pfizer 3-PHENYL-1-BENZOTHIOPEN-2-CARBOXYLIC ACID DERIVATIVES AS INHIBITORS OF BRANCHED ALPHA KETO ACID DEHYDROGENSIS KINASE FOR THE TREATMENT OF DIABETES, KIDNEY DISEASES, NASH AND HEART
CN116574084A (zh) * 2023-04-17 2023-08-11 华南理工大学 一种噻吩衍生物及其合成方法与应用
AU2025209211A1 (en) 2024-01-18 2026-07-30 Tuojie Biotech (Shanghai) Co., Ltd. Pyridothiophene-2-carboxylic acid derivative, preparation method therefor and use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517933A (ja) 2003-02-17 2006-08-03 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換された３−（ベンゾイルウレイド）−チオフェン誘導体その製造方法および使用
WO2011073298A1 (en) 2009-12-18 2011-06-23 Neurosearch A/S Tetrazole derivatives as nicotinic acetylcholine receptor modulators
JP2011524904A (ja) 2008-06-19 2011-09-08 ミレニアム・ファーマシューティカルズ・インコーポレイテッド チオフェン又はチアゾール誘導体及びｐｉ３ｋ阻害剤としてのそれらの使用
JP2014506895A (ja) 2011-03-03 2014-03-20 デノバメド インク． 抗菌性の化合物／アジュバント化合物および方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
DE3438830A1 (de) 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
JPH03204875A (ja) * 1989-10-03 1991-09-06 Wakamoto Pharmaceut Co Ltd テトラゾール酢酸誘導体、及び該誘導体を有効成分とするアルドースレダクターゼ阻害剤
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
ID26984A (id) 1998-07-06 2001-02-22 Bristol Myers Squibb Co Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
EA011086B9 (ru) 2004-05-12 2012-08-30 Пфайзер Продактс Инк. Производные пролина и их применение в качестве ингибиторов дипептидилпептидазы iv
EP2010520B1 (en) 2006-04-20 2012-09-12 Pfizer Products Inc. Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
CA2729581A1 (en) 2008-07-29 2010-02-04 Pfizer Inc. Fluorinated heteroaryls
ES2380408T3 (es) 2008-08-28 2012-05-11 Pfizer Inc. Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
WO2010034358A1 (en) 2008-09-29 2010-04-01 Nokia Siemens Networks Oy Apparatus, method, system and program for power control or power setting
TW201038580A (en) 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
WO2010103437A1 (en) 2009-03-11 2010-09-16 Pfizer Inc. Benzofuranyl derivatives used as glucokinase inhibitors
CA2754523A1 (en) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
CA2759843A1 (en) 2009-05-08 2010-11-10 Pfizer Inc. Gpr 119 modulators
EP2427448A1 (en) 2009-05-08 2012-03-14 Pfizer Inc. Gpr 119 modulators
GEP20135907B (en) 2009-06-05 2013-08-12 Pfizer L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
EP2954780A1 (en) 2009-07-24 2015-12-16 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
CN108779495A (zh) * 2016-04-06 2018-11-09 雀巢产品技术援助有限公司 调节bckdh的方法
WO2018109607A1 (en) 2016-12-16 2018-06-21 Pfizer Inc. Glp-1 receptor agonists and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517933A (ja) 2003-02-17 2006-08-03 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換された３−（ベンゾイルウレイド）−チオフェン誘導体その製造方法および使用
JP2011524904A (ja) 2008-06-19 2011-09-08 ミレニアム・ファーマシューティカルズ・インコーポレイテッド チオフェン又はチアゾール誘導体及びｐｉ３ｋ阻害剤としてのそれらの使用
WO2011073298A1 (en) 2009-12-18 2011-06-23 Neurosearch A/S Tetrazole derivatives as nicotinic acetylcholine receptor modulators
JP2014506895A (ja) 2011-03-03 2014-03-20 デノバメド インク． 抗菌性の化合物／アジュバント化合物および方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF BIOLOGICAL CHEMISTRY，2014年，289,30，20583-20593

Also Published As

Publication number Publication date
US20220363673A1 (en) 2022-11-17
JP2022538576A (ja) 2022-09-05
CA3144848C (en) 2023-11-21
WO2020261144A1 (en) 2020-12-30
EP3990452A1 (en) 2022-05-04
CA3144848A1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
US11542270B2 (en) BCKDK inhibitors
TWI718644B (zh) 用於治療ｎａｓｈ／ｎａｆｌｄ和相關疾病之組合
US9789110B2 (en) Diacylglycerol acyltransferase 2 inhibitors
JP7704982B2 (ja) 糖尿病、腎疾患、ｎａｓｈおよび心不全を処置するための分枝鎖アルファケト酸デヒドロゲナーゼキナーゼ阻害剤としての３－フェニル－１－ベンゾチオフェン－２－カルボン酸誘導体
JP2019524831A (ja) ジアシルグリセロールアシルトランスフェラーゼ２阻害剤
CN114787146A (zh) 二酰基甘油酰基转移酶2抑制剂
CA3144848C (en) 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
AU2023358062A1 (en) Hsd17b13 inhibitors and/or degraders
AU2021289169A1 (en) Spiro compounds as melanocortin 4 receptor antagonists and uses thereof
WO2019102256A1 (en) Pyridinone derivatives and their use as selective alk-2 inhibitors
CN118451066A (zh) 用于治疗糖尿病、肾病、NASH和心力衰竭的作为支链α酮酸脱氢酶激酶抑制剂的3-苯基-1-苯并噻吩-2-甲酸衍生物
RU2851700C2 (ru) Производные 3-фенил-1-бензотиофен-2-карбоновой кислоты в качестве ингибиторов киназы дегидрогеназы альфа-кетокислот с разветвленной цепью для лечения диабета, заболеваний почек, nash и сердечной недостаточности
EA049611B1 (ru) Производные 3-фенил-1-бензотиофен-2-карбоновой кислоты в качестве ингибиторов киназы дегидрогеназы альфа-кетокислот с разветвленной цепью для лечения диабета, заболеваний почек, nash и сердечной недостаточности

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230525

TRDD Decision of grant or rejection written
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240523

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240529

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240530